Protocol Ledger

NCT07111546 · Phase II · RECRUITING

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]

Interventional Phase II clinical trial protocol NCT07111546 sponsored by Nanjing Leads Biolabs Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-20 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07111546
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07111546
Protocol FieldVerified Registry Value
NCT IdentifierNCT07111546
Consolidated Lead SponsorNanjing Leads Biolabs Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2025-10-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI